Evidence map›Paper›PMID 40171507›Full record

ArticleFrontiers in medicine2025

A correlation study of serum tumor markers with systemic lupus erythematosus-associated interstitial lung disease.

Xing He, Jiaqi Ji, Ting Zhou, Zeli Luo, Siyu Fang, Xixi Chen, Chi Liu, Haiying Yan, Lu Guo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xing HeDepartment of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China.
Jiaqi JiDepartment of Pulmonary and Critical Care Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Ting ZhouDepartment of Pulmonary and Critical Care Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Zeli LuoDepartment of Critical Care Medicine, Wenjiang District People's Hospital of Chengdu, Chengdu, Sichuan, China.
Siyu FangDepartment of Pulmonary and Critical Care Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Xixi ChenDepartment of Rheumatology and Immunology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Chi LiuDepartment of Nephrology, Sichuan Academy of Medical Science and Sichuan Provincial People's Hospital, Sichuan Renal Disease Clinical Research Center, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Haiying YanDepartment of Pulmonary and Critical Care Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Lu GuoDepartment of Pulmonary and Critical Care Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Systemic lupus erythematosus-associated interstitial lung disease (SLE-ILD) is a pulmonary manifestation of SLE. Currently, serum biomarkers for early identification of SLE-ILD are lacking. Our study aimed to investigate the correlation and clinical significance of serum tumor markers (TMs) in patients with SLE-ILD. Methods: We conducted a retrospective analysis of medical records from SLE patients between January 2017 and November 2023. We compared the differences in serum levels of TMs including carcinoembryonic antigen (CEA), carbohydrate antigens (CA125, CA15-3, and CA19-9), squamous cell carcinoma antigen (SCC), cytokeratin-19-fragment (CYFRA21-1), neuron-specific enolase (NSE) and ferritin (FER), between SLE-ILD and SLE patients. Results: A total of 386 SLE patients were enrolled in this study, comprising 64 individuals with SLE-ILD. Compared with SLE group, SLE-ILD group exhibited higher serum levels of CEA, CA125, CA15-3, CA19-9, SCC, CYFRA21-1, and FER. Multivariate regression indicated that age (OR = 1.038, 95% CI = [1.004, 1.074]), CA15-3 (OR = 1.099, 95% CI = [1.039, 1.162]), and CA19-9 (OR = 1.032, 95% CI = [1.005, 1.059]) were associated factors for SLE-ILD ( Conclusion: Serum levels of CA125, CA15-3, and CA19-9 could act as associated markers for SLE-ILD. Serum SCC, CYFRA21-1 and FER levels may also be linked to kidney involvement in SLE-ILD.

Indexed as

biomarkersinterstitial lung diseaseorgan involvementsystemic lupus erythematosustumor markers

Identifiers

PMID40171507
PMCPMC11959046

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.